Pharmaceutical

Innovate UK grants funds for breast cancer therapy project

Innovate UK has awarded £1m grant for a collaborative initiative called AI-VISIO...

FDA grants breakthrough status to J&J’s nipocalimab for...

The FDA granted breakthrough therapy status for J&J's nipocalimab for pregnant p...

Science and menopause under the spotlight during the Su...

Super Bowl LVIII saw Astellas run awareness for hot flashes and Pfizer touchdown...

Disc wins orphan drug tag for rare blood cancer  

The humanised monoclonal antibody DISC-3405 is under investigation in a Phase I ...

First targeted alpha therapy wins FDA breakthrough devi...

RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) i...

CSL’s ‘big’ post-heart attack drug fails in Phase III t...

CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of m...

How AI data management can transform your clinical trial 

Vast quantities of data are only useful to researchers if that data can be easil...

Alys Pharmaceuticals announces launch with $100m funding

Alys Pharmaceuticals has announced its launch with a R&D pipeline, backed by a $...

MHRA agrees licence change for Pfizer-BioNTech’s Comirn...

The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s...

Opinion: What STAT readers think about Aduhelm, CTE and...

When a federal official talks about “public-private partnerships,” what they oft...

STAT+: In a showy hearing, Bernie Sanders gets few answ...

In a jam-packed hearing room, Sen. Bernie Sanders pressed CEOs with familiar que...

STAT+: Gilead sours on the ‘don’t eat me’ business

Gilead will no longer develop magrolimab, a treatment targeting the “don’t eat m...

Boehringer and CBmed partner to develop cancer therapies

Boehringer has entered a strategic collaboration with CBmed to expedite the tran...

AstraZeneca posts 81% rise in FY 2023 profit after tax

AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5...

BioNTech partners with Autolus to advance CAR-T therapies

BioNTech has entered into a strategic partnership with Autolus Therapeutics to p...

Hemogenyx gets reprieve as FDA lifts clinical hold on A...

The Phase I trial for evaluating Hemogenyx’s CAR-T therapy to treat acute myeloi...